Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medregen LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 2 examiners across 2 art units, requiring attention to separate technical and examination contexts.
MCMILLIAN, KARA RENITA is the busiest examiner, with 1 pending action. A coordinated portfolio position can support consistency, while each response should reflect the relevant examiner and art-unit practice.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18189741 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF TISSUE INJURY | MCMILLIAN, KARA RENITA | 89d overdue |
| 17684959 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS | BARRON, SEAN C | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18189741 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF TISSUE INJURY | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | 89d overdue | Pending | Mar 24, 2023 |
| 17684959 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS | BARRON, SEAN C | 1653 | §103DP | Final Rejection | 30d overdue | Pending | Mar 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedregen LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kara Renita Mcmillian has the most, with 1 of Medregen LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
